|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
44
|
|
pubmed:dateCreated |
1984-2-14
|
|
pubmed:abstractText |
Forty-three patients with small-cell bronchial carcinoma were treated with sequential combination chemotherapy of the CMC-VAP type alternating every 6 weeks. Toxicity affected mostly blood cells and occurred during induction. The response rate was 60% in circumscribed forms with a median survival of 15 months, and 30% in diffuse forms with a median survival of 6 months. The value of alternating protocols and the place of radiotherapy are discussed in the light of these results.
|
|
pubmed:language |
fre
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0755-4982
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
3
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2805-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:6318213-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:6318213-Bronchial Neoplasms,
pubmed-meshheading:6318213-Carcinoma, Small Cell,
pubmed-meshheading:6318213-Combined Modality Therapy,
pubmed-meshheading:6318213-Cyclophosphamide,
pubmed-meshheading:6318213-Doxorubicin,
pubmed-meshheading:6318213-Female,
pubmed-meshheading:6318213-Humans,
pubmed-meshheading:6318213-Lomustine,
pubmed-meshheading:6318213-Male,
pubmed-meshheading:6318213-Methotrexate,
pubmed-meshheading:6318213-Neoplasm Recurrence, Local,
pubmed-meshheading:6318213-Procarbazine,
pubmed-meshheading:6318213-Vincristine
|
|
pubmed:year |
1983
|
|
pubmed:articleTitle |
[Triple biphasic chemotherapy in the treatment of small-cell bronchial cancer].
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
